newsfilter
← Latest News
GlobeNewswire·

Vaxart Provides Business Update and Reports Full Year 2025 Financial Results

VXRT
  • Vaxart announced Phase 2b COVID-19 trial topline data from its 400-person sentinel cohort is anticipated in early Q2 2026.
  • Positive clinical results published in Q1 2026 confirmed the oral norovirus vaccine candidate was safe, immunogenic in lactating women, and facilitated passive antibody transfer to infants via breast milk.
  • The Company reported cash, cash equivalents, and investments of $63.8 million as of December 31, 2025, with a runway extending into Q2 2027.
  • Vaxart completed enrollment of approximately 5,400 participants in its COVID-19 Phase 2b trial, consisting of a 400-person sentinel cohort and a 5,000-person KP.2 cohort.
  • Full trial data for the COVID-19 Phase 2b study comparing the oral pill to mRNA vaccines is expected in Q4 2026, following 12 months of monitoring.
  • Revenue for the full year 2025 reached $237.3 million, driven by government contracts under the BARDA award and revenue from the Dynavax collaboration signed in November 2025.
  • Research and development expenses increased to $201.6 million in 2025 compared to $74.2 million in 2024 due to higher clinical trial costs.
  • The Company reported a net income of $16.3 million for 2025, a significant improvement from the net loss of $66.9 million recorded in 2024.
  • A conference call to discuss business updates and financial results is scheduled for March 12, 2026, at 4:30 p.m. ET.
  • A live stockholder fireside chat is scheduled for March 13, 2026, at 4:30 p.m. ET to address frequently asked questions.
  • Pending new partnerships or funding, Vaxart plans to initiate its next norovirus clinical trial in 2026.